ARID1A and neoplasm: Interestingly, several studies (Allo et al., 2014; Reske et al., 2021; Wu et al., 2017; Xu and Tang, 2021) have shown that TP53 and ARID1A are frequently mutated across cancer samples but rarely in the same primary tumour.